Novo Holdings acquires US-based home infusion therapy firm
Kabafusion, a US-based provider of antibody-based infusion therapies that can be administered at a patient’s home, has been acquired by Novo Holdings.
by ulrich quistgaard, translated by daniel pedersen
Novo Holdings is taking over the keys to a US-based provider of home infusion therapies, Kabafusion, the Danish company announced in a Wednesday press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Holdings invests USD 50m in South Asian genome company
For subscribers
